Aldeyra Seeks FDA Division Transfer for ADX-2191, Withdraws Agreed SPA Protocol
ALDX sits 21% above its 52-week low of $0.527.
Summary
Aldeyra asked the FDA to move its ADX-2191 lymphoma IND to the hematologic malignancies division and withdrew the previously agreed SPA protocol, leaving the PVRL trial without an agreed design and the program facing redesign, delay and potentially higher costs.
Key Events · Product Development and Regulatory · ALDX
-
Jurisdiction Transfer Requested for ADX-2191
Aldeyra asked the Division of Ophthalmology to submit a review jurisdiction request to the Office of New Drugs recommending the ADX-2191 IND for primary vitreoretinal lymphoma move to the Division of Hematologic Malignancies 2.
-
Agreed SPA Protocol Withdrawn
The company notified the FDA it withdrew the Special Protocol Assessment protocol for ADX-2191 in PVRL that the Division of Ophthalmology had previously reviewed and agreed to, so it loses the benefit of that agreed trial design.
-
PVRL Trial on Hold Pending FDA Decision
Aldeyra does not expect to initiate the SPA-contemplated trial while the request is pending; the division controls whether to submit it and the Office of New Drugs has discretion to deny it or assign a different division.
-
Redesign Could Raise Costs and Cut Runway
A redesigned trial may be larger, longer or more costly, harder to enroll given PVRL's rarity, and could delay or prevent orphan drug exclusivity; the filing says this could shorten projected cash runway and require raising capital sooner than expected.
Analysis · ALDX · Life Sciences
Aldeyra has asked the FDA's Division of Ophthalmology to hand review of its ADX-2191 IND for primary vitreoretinal lymphoma to the Division of Hematologic Malignancies 2, arguing that lymphoma reviews belong with that group's expertise. In the same breath, it withdrew the Special Protocol Assessment the ophthalmology division had already agreed to, so the company no longer has a pre-cleared trial design and does not expect to start the planned trial while the request is pending. The decision sits entirely with the FDA: the division may never submit the request, and the Office of New Drugs may deny it or send the IND somewhere other than DHM2. Either way, the PVRL program needs redesigning, and the filing warns a new trial could be larger, longer, costlier and harder to enroll given how rare the disease, with a risk of losing orphan drug exclusivity if a competing methotrexate-based product gets there first. That pushes any NDA resubmission further out and could shorten the cash runway the company just reported as extending into 2029, forcing a raise sooner than planned. It also lands while Aldeyra is appealing the separate reproxalap dry eye rejection, so both legs of the story now hinge on FDA discretion.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALDX was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.4M. The 52-week trading range was $0.53 to $5.93. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.